Filing Flows › 20/20 Biolabs (AIDX) › Q1 2026
20/20 Biolabs (AIDX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 20, 2026
20/20 Biolabs (AIDX) reported revenue of $353K for the first quarter 2026 (Q1 2026), -36% from a year earlier. Operating margin was -408.4%, net loss $2.2M (615.4% of revenue).
20/20 Biolabs, Q1 2026: revenue $353K (-36% year over year), operating margin -408.4%, net loss $2.2M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $353K | — | -36% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$2.2M | — | — |
| Operating cash flow | −$1.3M | — | — |
What changed
Revenue was $353K in Q1 2026, down 36% year over year. One Test was the largest line at 88% of revenue. One Test lost $161K year over year (down 34%), 80% of the total change.
Gross margin was 17.8%, down 12.1 points from a year earlier. Operating costs exceeded revenue by $1.4M, an operating margin of -408.4%. Operating expenses grew 61% against a revenue fall of 36%. The fastest-growing cost line was SG&A (+69%). The quarter ended with a net loss of $2.2M.
Operating cash flow was −$1.3M. Non-cash charges added back $12K of depreciation and amortization and $128K of share-based compensation. Working capital and other items added $745K.
Questions
What was 20/20 Biolabs' revenue in the first quarter 2026?
20/20 Biolabs (AIDX) reported revenue of $353K for the first quarter 2026 (Q1 2026), -36% from a year earlier.
Was 20/20 Biolabs profitable in the first quarter 2026?
Operating loss was $1.4M (-408.4% of revenue) and net loss $2.2M.
Source: 20/20 Biolabs 10-Q on SEC EDGAR.